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The receipt rate of hepatitis B virus vaccine among adolescents in
the United States is high, while the receipt rate of human papillo-
mavirus  vaccine  is  low.  Rates  have  not  been  closely  studied
among refugees, whose home countries have high rates of disease
caused by these viruses.
Methods
We examined human papillomavirus and hepatitis B virus immun-
ization rates among 2,269 refugees aged 9 to 26 years who re-
settled in Massachusetts from 2011 through 2013. This was a sec-
ondary analysis of data from their medical screenings. We used
binary logistic regression to assess characteristics associated with
immunization and bivariate analyses to compare refugee immuniz-
ation rates with those of the general US population.
Results
Forty-five percent of US adolescents aged 13 to 17 years received
1 dose of human papillomavirus vaccine, compared with 68% of
similarly aged refugees. Males (adjusted odds ratio [aOR], 0.62;
95% confidence interval [CI], 0.52–0.74), refugees older than 13
years (aOR, 0.74; 95% CI, 0.60–0.93), and refugees not from Sub-
Saharan Africa (aOR, 0.74; 95% CI, 0.59–0.92) were less likely to
receive human papillomavirus  vaccine,  while  arrivals  in  2012
through 2013 were more likely (aOR, 1.6; 95% CI, 1.3–1.9) than
those arriving in 2011. Refugees older than 13 years were less
likely to receive 2 doses of hepatitis B virus vaccine (aOR, 0.49;
95% CI, 0.37–0.63) than older refugees.
Conclusion
Specialized post-arrival health assessment may improve refugees’
immunization rates.
Introduction
Since 2009, approximately 70,000 refugees each year resettle in
the United States. Of these, 30% to 40% are children (1). Refugee
children immigrate with substantial preventable health problems,
including infectious diseases, elevated lead levels, dental prob-
lems, and poor nutrition (2–4), and have low overall immuniza-
tion rates (5). Language and cultural differences, poverty, trauma,
and lack of insurance are barriers to care once resettled (4,6).
Cervical cancer and sequelae of hepatitis B infection are more
common in refugees’ countries of origin than in the United States.
These conditions are caused by human papillomavirus (HPV) and
hepatitis B virus (HBV), respectively, and each condition is pre-
ventable with a 3-dose vaccine series (7–10). Although HBV im-
munization rates are high in the United States, with 93% of those
aged 13 to 17 years receiving the series in 2013, only 45% of US
adolescents initiated the newer HPV vaccine series in 2013. For
both vaccines, disparities in coverage exist by race and ethnicity
(11). Patients’ and providers’ attitudes and beliefs, parent educa-
tion, insurance status, and having a reliable source of health care
can influence receipt of immunization (12).
Although studies have explored disparities in immunization by
race and ethnicity, they have not examined data on immunization
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among refugees, who differ from other immigrants by countries of
origin, medical conditions, experiences with the health care sys-
tem (post-arrival medical screening), and trauma. The objective of
this  study  was  to  analyze  HPV and  HBV immunization  rates
among refugee children resettled in Massachusetts, to examine so-
ciodemographic  factors  associated  with  immunization  among
refugees, and to compare immunization rates among refugees with
those of the general US population. We anticipated that our find-
ings would facilitate culturally relevant immunization and prevent-
ive health services for refugees.
Methods
Study design, participants, and data collection
This study entailed a secondary analysis of data from a cohort of
refugees  resettled  in  Massachusetts  from 2011  through  2013.
Nearly  all  refugees  resettled  in  Massachusetts  are  screened
through the Refugee Health Assessment Program (RHAP) of the
Massachusetts Department of Public Health (MDPH). RHAP is a
contracted network of 12 private clinic sites and community health
centers that provides health screening and immunization accord-
ing to a clinical protocol established by MDPH for refugees re-
settled in Massachusetts. RHAP serves as initial access to primary
care services, with each new refugee having 2 visits within 90
days of arrival (4). During an RHAP visit, refugees undergo vis-
ion, hearing, behavioral health, and dental screening; have laborat-
ory samples drawn to screen for hepatitis B, parasites, human im-
munodeficiency virus, anemia, vitamin D deficiency, abnormal ur-
ine chemistry, and exposure to tuberculosis; receive immuniza-
tions per guidelines of the Centers for Disease Control and Pre-
vention (CDC); and are provided information about how to access
health care in Massachusetts (4,13).
The study sample consisted of all refugees aged 9 to 26 years re-
settled  in  Massachusetts  from 2011  through  2013  with  docu-
mented medical screening through RHAP. Data were extracted
from  the  Massachusetts  Virtual  Epidemiologic  Network
(MAVEN), which is the MDPH’s web-based surveillance and case
management system (14).  MAVEN includes demographic and
clinical data derived from health screenings overseas and shortly
after arrival in Massachusetts. Examples of the clinical data in-
clude  anthropometrics  and  vital  signs,  health  conditions  dia-
gnosed overseas and domestically, dates of immunizations, screen-
ing test results, and medications prescribed pre-arrival and post-ar-
rival (15).
Measures
The primary outcomes of interest were receipt of 1 dose of HPV
vaccine and 2 doses of HBV vaccine pre-arrival and post-arrival.
We chose to look at 1 dose of HPV vaccine and 2 doses of HBV
vaccine because timing of RHAP visits does not allow for comple-
tion of either series.  Refugees often receive their  first  dose of
HBV vaccine overseas, but HPV vaccine is generally not avail-
able in the countries from which refugees in Massachusetts mi-
grate (16). Therefore, the expectation was that the initial dose of
HPV vaccine would be given during an RHAP visit. We extracted
data for the following predictor variables: date of arrival, age, na-
tionality, sex, race, presence of acute or chronic medical condi-
tions,  HBV surface antigen status,  anti-HBV surface antibody
status, and total number of vaccines received pre-arrival and post-
arrival (not aggregated by vaccine type). Nationality was categor-
ized by world region of origin, based on US Department of State
regional categories. Three countries — Somalia, Iraq, and Bhutan
— were evaluated separately from their world region categories
because they had a sufficient number of refugee arrivals to war-
rant individual analyses. We examined data on acute and chronic
medical conditions to control for clinicians’ decisions to postpone
vaccination because of illness. We also extracted data for the cov-
ariates of dates of RHAP clinic visits and the RHAP clinic site.
We converted 2 continuous variables into categorical variables for
facilitation of analysis. We converted age to a dichotomous vari-
able — 9 to 12 years or 13 to 26 years — to separate refugees who
had been vaccinated per CDC guidelines at age 11 or 12 years
from those who had received the vaccine later. We also converted
year of arrival to a dichotomous variable — arriving in 2011 or ar-
riving in 2012 through 2013 — to examine whether vaccination
rates changed when RHAP began emphasizing the administration
of new vaccines, such as the meningococcal conjugate vaccine and
the HPV vaccine, in 2012.
Analyses
We calculated means and standard deviations for all continuous
variables and frequencies for all categorical variables. We then
performed bivariate analyses (t test and χ2 analyses, as appropri-
ate) to assess associations between HPV and HBV immunization
and the variables  listed above.  Significance was based on a  P
value of less than .05. On the basis of these results, we conducted
logistic regression analyses to assess factors associated with vac-
cine receipt. The variables included in the logistic regression for
HPV immunization were age group, sex, RHAP site, arrival year,
and world region of origin. The world region of origin variable
was dichotomized for the logistic regression into 1) Sub-Saharan
Africa, excluding Somalia, and 2) other regions. These were di-
chotomized because this region had the highest rate of HPV im-
munization among the regions studied. The variables included in
the logistic regression for HBV immunization were age group,
RHAP site, HBV surface antigen status, and anti-HBV surface an-
tibody  status.  Lastly,  we  compared  HPV  immunization  rates
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among refugees aged 13 to 17 years with rates in the general US
population and the general Massachusetts population of the same
age, based on National Immunization Survey (NIS) data, using χ2
analyses. We used SAS version 9.3 (SAS Institute, Inc) to con-
duct our statistical analyses. This study was approved by the au-
thors’ institutional review boards and was monitored by MDPH’s
Institutional Review Board.
Results
From 2011 through 2013, 2,269 refugees aged 9 to 26 years were
resettled in Massachusetts. Predominant nationalities were Iraqi
(25%), Bhutanese (24%), and Somali (11%) (Table 1). Refugees
received a mean of 9.3 individual vaccines (range, 0 to 31), ad-
ministered both overseas and at RHAP visits. No single variable
had greater than 3% of values missing, and over 95% of refugees
included in the analysis had complete data.
Fifty-six percent of all refugees aged 9 to 26 years received 1 dose
of  HPV vaccine,  either  pre-arrival  or  post-arrival.  Among all
refugees, those who received 1 dose of HPV vaccine received 3.3
more vaccines than refugees who did not receive HPV vaccine (P
< .001). Males were less likely than females to receive HPV vac-
cine (adjusted odds ratio [AOR], 0.62; 95% confidence interval
[CI]. 0.52–0.74). Refugees aged 13 to 26 years were less likely to
receive HPV vaccine than refugees aged 9 to 12 years (AOR, 0.74;
95% CI, 0.60–0.93). Refugees who were not from Sub-Saharan
Africa, excluding Somalia, were less likely than refugees from this
region to receive HPV vaccine (AOR, 0.74; 95% CI, 0.59–0.92).
Arrivals in 2012 through 2013 were more likely to receive HPV
vaccine than refugees who arrived in 2011 (AOR, 1.6; 95% CI,
1.3–1.9). The only relevant acute or chronic medical conditions
present among this sample of refugees were acute upper respirat-
ory infections and ear abnormalities and infections,  neither of
which was found to be significantly associated with receipt of 1
dose of HPV vaccine. Rates of HPV immunization varied signific-
antly by RHAP clinic site.
Rates of HBV immunization varied: 91% of refugees received at
least 1 dose, 63% received 2 doses, and 10% received 3 doses.
Timing of RHAP visits, typically 1 month apart, generally does
not  permit  administration  of  a  third  dose,  which  should  be  2
months after the second dose and 6 months after the first dose.
Refugees aged 13 to 26 years were less likely to receive 2 doses of
HBV vaccine than refugees 9 to 12 years old (AOR, 0.49; 95% CI,
0.37–0.63) (Table 2). Refugees with positive HBV surface anti-
gen or antibody were less likely to receive 2 doses than those with
negative antigen (AOR, 0.13; 95% CI,  0.07–0.24) or antibody
(AOR, 0.42; 95% CI, 0.34–0.52) status. Nationality, year of ar-
rival, sex, and presence of acute upper respiratory infections or ear
abnormalities and infections were not significantly associated with
receipt of HBV vaccine. Furthermore, we found no significant dif-
ference in receipt of 2 doses of HBV vaccine among refugees who
had received 1 or more doses overseas or both doses during RHAP
visits.
Refugee adolescents aged 13 to 17 years resettled in Massachu-
setts had higher rates of receipt of 1 dose of HPV vaccine than ad-
olescents in the general US population. Per NIS data for the US
population, in 2013, 45% of those aged 13 to 17 years received 1
dose  of  HPV  vaccine  compared  with  68%  of  similarly  aged
refugees (odds ratio [OR], 2.5; 95% CI, 2.1–3.0). NIS data for the
US population also showed that 57% of females and 35% of males
aged  13  to  17  years  received  1  dose;  data  for  Massachusetts
showed that 62% of females and 53% of males in this age group
received 1 dose. RHAP data for this age group showed that 68%
of female refugees (compared with US females: OR, 1.6; 95% CI,
1.2–2.1) and 68% of male refugees (compared with US males:
OR, 3.9; 95% CI, 3.1–5.0) received 1 dose (11). Data were not
available to calculate ORs for Massachusetts.
Discussion
HBV immunization rates among refugees were higher than HPV
immunization rates, with 91% of refugees receiving 1 dose and
63% of refugees receiving 2 doses of HBV vaccine.  Refugees
aged 13 to 26 years and refugees with positive HBV surface anti-
gen had significantly lower rates of receipt of 2 doses of HBV
vaccine than younger refugees and refugees with negative HBV
surface antigen status. We had a similar finding for refugees who
were positive for anti-HBV surface antibodies. This latter finding
suggests that clinicians did not finish incomplete HBV vaccine
series started overseas if the titer was positive. Lack of compar-
able  data  precluded  comparison  of  HBV  immunization  rates
among refugees with national and state data.
Our finding that female refugees were significantly more likely
than male refugees to receive 1 dose of HPV vaccine is consistent
with trends in the general population. These results are likely ex-
plained by the later recommendation for male vaccination. The
CDC’s Advisory Committee on Immunization Practices (ACIP)
first recommended HPV vaccine in 2006 for females aged 11 to 12
years, with catch-up vaccination for women up to age 26. The
ACIP began recommending HPV vaccine for males aged 11 to 12
years in 2011, with catch-up vaccination for men up to age 21
(17). These results also may be explained by the general popula-
tion’s stronger association of HPV with cervical cancer than with
cancers that affect men (18).
The higher rates of HBV immunization compared with those for
HPV immunization among refugees may be explained by the prac-
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tice of administering 1 or more doses of HBV vaccine to refugees
before their departure to the United States and the unavailability of
HPV vaccine in their countries of origin. Although HBV vaccine
is widely available and used around the world, the HPV vaccine is
available and recommended mainly in countries in Europe and
North and South America; however, most refugees resettled in
Massachusetts did not originate in these regions (16).
The higher rates of HPV immunization among refugee adoles-
cents compared with the general US adolescent population was
unexpected, particularly given disparities in health and access to
care by race and ethnicity as well as language and cultural barriers.
Furthermore,  studies  have identified a  lack of  knowledge and
awareness about HPV as well as certain beliefs about the vaccine
among specific ethnic and racial groups that deter caregivers from
initiating  HPV vaccination  for  their  children.  Two studies  of
Latino parents showed that lack of knowledge about HPV, con-
cerns about side effects, out-of-pocket costs, and concerns that the
vaccine promotes sexual activity discourage parents from immun-
izing their  children against  HPV (19,20).  Furthermore,  among
Cambodian American women, major barriers to HPV vaccination
were lack of information and concerns about safety, cost, and ef-
fectiveness, while primary factors facilitating vaccination were
provider recommendation and belief in the importance of disease
prevention (21). When looking across racial and ethnic groups,
one  study  among  Latin  American,  Asian  American,  African
American, and white women showed that fewer first-generation
immigrants had heard of HPV and had lower knowledge of HPV
compared with those who were second- and third-generation im-
migrants (22). The findings of our study suggest that the refugee
populations we studied may differ from these immigrant popula-
tions. As the literature suggests, many caregivers hesitate to ad-
minister HPV vaccine to their children for cultural and religious
reasons. It is possible that refugees are not aware of these hesita-
tions and therefore do not object to administering the HPV vac-
cine to their children.
CDC has made several recommendations to address these hesita-
tions. One factor that encourages caregivers to immunize their
children against HPV is clinician recommendation (21–25), which
may be particularly important for immigrants and refugees with
limited access to health information (26). CDC therefore urges
clinicians to encourage HPV vaccination and proposes doing so by
making it  routine. CDC suggests that clinicians tell  caregivers
“your child needs these vaccines today” and then list all of the
vaccines, including HPV, for which the child is eligible by age
(27). CDC also recommends that when discussing HPV vaccine
with caregivers, providers highlight that the vaccine is a means to
prevent cancer, is safe and effective, is for males and females, and
should be given to children before possible virus exposure (28).
Applying these prior studies’ findings and CDC guidelines, the
HPV and HBV vaccines are recommended by clinicians and made
normative at every RHAP visit because they are part of the pro-
gram’s  clinical  protocol  requiring  clinicians  to  follow  ACIP
guidelines. Given that the ACIP immunization schedule includes
HPV vaccination for both males and females at 11 or 12 years old,
RHAP clinicians may have been more likely to administer HPV
vaccine to refugees of both sexes in this age group than to older
refugees, explaining the higher HPV and HBV immunization rates
of younger refugees and the equal rates of HPV immunization
among male and female refugees aged 13 to 17 years.
The higher rates of HPV immunization among refugees resettled
later in our study period were not surprising. RHAP began em-
phasizing the administration of HPV vaccine in late 2012 through
annual oversight meetings with clinical staff at all RHAP sites,
through 2 conference calls with audiovisual materials to support
updates in the RHAP clinical protocol, and through email remind-
ers. The higher HPV immunization rates later in our study period
may also be explained by a shift in cultural norms and greater ac-
ceptance of the HPV vaccine in the United States as a whole, as
rates of HPV immunization increased significantly from 2012 to
2013 for adolescent females and from 2011 to 2012 as well as
from 2012 to 2013 for adolescent males (29).
Our study thus suggests that the use of a clinical immunization
protocol by clinics specifically contracted by MDPH to perform
health assessment of newly arrived refugees greatly increases vac-
cine receipt for refugees. Given the efficacy of the HPV and HBV
vaccines in preventing cancer and liver disease, the adoption of
provider recommendation and standardization of these vaccines in
practice across the United States has positive public health implic-
ations in preventing illness and death from these viruses (9,28).
This study has several limitations. First, immunization rates of
refugees resettled only in Massachusetts were assessed, and our
data  may not  be generalizable  to  refugee populations in  other
states.  Different  refugee  populations  are  resettled  in  different
states (30), and states have different policies and procedures for
resettlement (4). Immunization rates also vary by state, and the
general adolescent population in Massachusetts has higher HPV
immunization rates than the general adolescent population in oth-
er states (11). Second, because most refugees have only 2 RHAP
visits, the data did not allow review of series completion for both
the HPV and HBV vaccines. Third, the study was a secondary
analysis of an existing data set that did not address why refugees
or their caregivers did or did not choose to initiate HPV vaccina-
tion,  how providers  discussed  the  vaccine,  or  to  what  extent
RHAP clinic sites standardized HPV immunization. Furthermore,
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research is needed to evaluate refugee immunization rates in other
states, to determine refugees’ full-series completion rates for both
vaccines, and to explore reasons for the different rates, such as
refugees’ attitudes and beliefs, provider characteristics, and clinic
protocols.
With already high rates of HBV and other immunizations, both
among refugees and the general population in the United States,
efforts should be directed to promote use of HPV vaccine among
refugees and others. Through a collaborative campaign to pro-
mote HPV vaccination, both through universal clinician recom-
mendation and through standardization of HPV vaccination, it is
hoped that rates of HPV immunization of refugees and other chil-
dren will continue to rise.
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Sub-Saharan Africa, excluding Somalia 481 (21)
Somalia 255 (11)
Near East, excluding Iraq 24 (1)
Iraq 571 (25)
South and Central Asia, excluding Bhutan 29 (1)
Bhutan 538 (24)
East Asia and Pacific 214 (9)
Europe and Eurasia 64 (3)
Western Hemisphere 93 (4)
a One refugee had missing data for sex.
b Ten refugees had missing data for race.
c World regions are the regions used by the US Department of State. Three countries — Somalia, Iraq, and Bhutan — were evaluated separately from their world re-
gion categories because they had a sufficient number of refugee arrivals to warrant individual analyses.
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Table 2. Refugee Characteristics Predictive of Vaccine Receipt (N = 2,269), Massachusetts Department of Public Health, 2011–2013
Characteristic Human Papillomavirus Hepatitis B Virus
Age, y (reference: 9–12 y), adjusted odds ratio (95% confidence interval)
13–26 years 0.74 (0.60–0.93) 0.49 (0.37–0.63)
Sex (reference: female), adjusted odds ratio (95% confidence interval)
Male 0.62 (0.52–0.74) 1.1 (0.94–1.3)
Arrival year (reference: 2011), adjusted odds ratio (95% confidence interval)
2012–2013 1.6 (1.3–1.9) 0.87 (0.70–1.1)
Hepatitis B virus surface antigen (reference: negative), adjusted odds ratio (95% confidence interval)
Positive Does not apply 0.13 (0.07–0.24)
Hepatitis B virus surface antibody (reference: negative), adjusted odds ratio (95% confidence interval)
Positive Does not apply 0.42 (0.34–0.52)
Region, % (n) [P valuea]
Sub-Saharan Africa, excluding Somalia (N = 481) 63 (302) [Reference] 68 (326) [Reference]
Somalia (N = 255) 51 (129) [.001] 50 (127) [<.001]
Near East, excluding Iraq (N = 24) 29 (7) [.002] 42 (10) [.01]
Iraq (N = 571) 61 (350) [.62] 59 (338) [.004]
South and Central Asia, excluding Bhutan (N = 29) 41 (12) [.03] 57 (17) [.31]
Bhutan (N = 538) 56 (301) [.03] 68 (364) [.97]
East Asia and Pacific (N = 214) 56 (119) [.07] 66 (141) [.49]
Europe and Eurasia (N = 64) 23 (15) [<.001] 50 (32) [.006]
Western Hemisphere (N = 93) 48 (45) [.009] 71 (66) [.61]
a χ2 analysis.
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